An update from HUTCHMED (China) Limited ( (HK:0013) ) is now available.
HUTCHMED (China) Limited announced the release of its 2024 Annual Report and Notice of Annual General Meeting, which will be available to shareholders who opted for printed copies and accessible online. The 2025 Annual General Meeting will be conducted as a hybrid event, allowing both physical and online participation, highlighting the company’s commitment to accessibility and transparency for its stakeholders.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
YTD Price Performance: -4.89%
Average Trading Volume: 46,607
Technical Sentiment Signal: Strong Buy
Current Market Cap: £2.13B
Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.